Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Mapa de calor
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
X
XBI
State Street SPDR S&P Biotech ETF
136.2
0
USD
+9917.65%
Setor:
Finanças
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+9917.65%
Mudança mensal
+5.17%
Mudança em 6 meses
+11.88%
Mudança anual
+23.67%
Fechamento anterior
1.3
6
Open
136.4
8
Mínimo
136.1
5
High
136.7
3
Volume
649
Mercados
US ETFs
XBI
Abrir gráfico completo
Full chart
Visão geral
Todos os ativos
Mapa de calor
Principais ativos
Market Value
Shares
Weight %
D
DAWN
Day One Biopharmaceuticals Inc
24.2 M
2.6 M
0.3%
ORIC
ORIC Pharmaceuticals Inc
24.0 M
2.9 M
0.3%
REPL
Replimune Group Inc
22.7 M
2.3 M
0.3%
SPRY
ARS Pharmaceuticals Inc
22.3 M
1.9 M
0.3%
IBRX
ImmunityBio Inc
19.9 M
10.1 M
0.3%
ORKA
Oruka Therapeutics Inc
19.3 M
637.7 K
0.2%
CTMX
CytomX Therapeutics Inc
19.3 M
4.5 M
0.2%
OLMA
Olema Pharmaceuticals Inc
18.6 M
745.8 K
0.2%
RAPT Therapeutics Inc
18.5 M
546.6 K
0.2%
SANA
Sana Biotechnology Inc
18.5 M
4.5 M
0.2%
EBS
Emergent BioSolutions Inc
18.2 M
1.5 M
0.2%
GERN
Geron Corp
18.0 M
13.6 M
0.2%
KALV
KalVista Pharmaceuticals Inc
17.6 M
1.1 M
0.2%
GLUE
Monte Rosa Therapeutics Inc
17.5 M
1.1 M
0.2%
UPB
Upstream Bio Inc
17.4 M
641.1 K
0.2%
SION
Sionna Therapeutics Inc
16.8 M
409.1 K
0.2%
LXEO
Lexeo Therapeutics Inc
16.8 M
1.7 M
0.2%
BCAX
Bicara Therapeutics Inc
16.7 M
991.2 K
0.2%
VSTM
Verastem Inc
16.5 M
2.1 M
0.2%
GOSS
Gossamer Bio Inc
16.1 M
5.2 M
0.2%
1
2
3
4
5
6
7
8
Notícias
First Quarter Earnings: Sharpening Sector Divergence
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
3 Reasons To Stick With Growth Stocks In Rotating Markets
Seeking Innovation Beyond Tech? Insight On Healthcare Stocks
Biotech Investors Are Tuning Out the MAHA Chaos
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)
Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA
FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint
Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)
Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird
Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita